Questcor to Present At the Oppenheimer 19th Annual Healthcare Conference in New York

* Reuters is not responsible for the content in this press release.

Thu Oct 23, 2008 6:01am EDT 

UNION CITY, Calif., Oct. 23, 2008 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals,
Inc. (Nasdaq:QCOR) announced today that it will present at the Oppenheimer 19th
Annual Healthcare Conference on Tuesday, November 4, 2008 at the Waldorf-Astoria
Hotel in New York City. Steve Cartt, Executive Vice President, Corporate
Development and Dave Medeiros, Senior Vice President of Pharmaceutical
Operations will discuss the Company's business strategy and financial
performance at 4:00 p.m. Eastern Time.

Attendance at the conference is by invitation only. A live audio webcast of
Questcor's presentation may be accessed through the Company's website at
www.questcor.com. An archived replay of the presentation will be available after
the live presentation, and can also be accessed at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two
commercial products, H.P. Acthar(r) Gel ("Acthar") and Doral(r). Acthar
(repository corticotropin injection) is an injectable drug that is approved for
the treatment of certain disorders with an inflammatory component, including the
treatment of exacerbations associated with multiple sclerosis ("MS"). In
addition, Acthar is not indicated for, but is used in treating patients with
infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and
opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological
disorder. Doral is indicated for the treatment of insomnia characterized by
difficulty in falling asleep, frequent nocturnal awakenings, and/or early
morning awakenings. The Company is also developing QSC-001, a unique orally
disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen
for the treatment of moderate to moderately severe pain. For more information,
please visit www.questcor.com.

-0-
CONTACT:  Questcor Pharmaceuticals, Inc.
          Don Bailey
          510-400-0776
          dbailey@Questcor.com

          EVC Group, Inc.
          Investors
          Doug Sherk
            415-896-6820
          Dahlia Bailey
            415-896-5862
          Media
          Steve DiMattia
            646-201-5445
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.